TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Clinical Trial Club | Optimal treatment sequencing and ongoing clinical trials in anemic myelofibrosis (highlights)

Featured:

Angela FleischmanAngela Fleischman

Mar 13, 2024


Video series

On February 26, 2024, Scientific Education Support hosted a Clinical Trial Club entitled “Treatment sequencing for anemic myelofibrosis.” This live webinar was part of the MPN Hub Clinical Trial Club webinar series, “Novel agents for the treatment of anemic myelofibrosis.”  

During the live webinar, myeloproliferative neoplasms expert, Angela Fleischman, discussed optimal treatment sequencing in anemic myelofibrosis, as well as reviewing key data from recent clinical trials investigating luspatercept and pacritinib. This video captures some of the highlights from her presentation, while the full video is available here. 

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content